ArticleProbiotics and antimicrobial proteins2026
In Vitro Antiviral-Associated Evaluation of Selected Prebiotics, Probiotic-Derived Preparations, and Synbiotic Formulations Against HSV-1 and VSV.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the in vitro antiviral-associated effects of prebiotics, probiotic-derived preparations, and synbiotic formulations against Herpes simplex virus type 1 (HSV-1) and vesicular stomatitis virus (VSV) in Vero cells. Lactobacillus acidophilus, L. rhamnosus, and L. plantarum preparations were tested as cell-free supernatants, cell sonicates, and combinations with plant-derived prebiotic extracts. Cytotoxicity was assessed using the MTT assay to determine non-cytotoxic concentrations, while antiviral activity was evaluated by cytopathic effect (CPE)-based TCID50 endpoint titration. Several preparations produced statistically significant reductions in viral infectivity compared with untreated controls (p < 0.05). Among the tested preparations, L. plantarum and L. acidophilus showed the greatest reductions in infectivity, with reductions reaching approximately 41.66% for HSV-1 and 38.88% for VSV under the tested experimental conditions. Selected synbiotic formulations also demonstrated measurable reductions in infectivity. These findings suggest that probiotic-derived preparations and synbiotic formulations may reduce infectivity of both DNA and RNA viral models in vitro and warrant further investigation as adjunct antiviral strategies.
Indexed as
Identifiers
42545606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.